Preclinical study underpins efficacy of Paradigms RhinosulR
Filed with ASX · · 2 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm PPS a potential in the treatment of viral arthritis
- Preliminary Final Report
- Paradigm PPS nasal spray to treat Allergic Rhinitis
- Shareholders Update
- ASX Admission Market Release
Later from Paradigm Biopharmaceuticals
- Paradigms Placement heavily oversubscribed
- Appendix 4C - September 2016 quarter
- Paradigms hay fever clinical trial cleared to commence
- Recruitment complete in Paradigms hay fever clinical trial
- Quarterly Cashflow Report
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals